308-nm excimer lamp with 0.03% tacrolimus ointment is safe and effective to treat children with non-segmental vitiligo
- PMID: 36686005
- PMCID: PMC9837576
- DOI: 10.5114/ada.2022.122606
308-nm excimer lamp with 0.03% tacrolimus ointment is safe and effective to treat children with non-segmental vitiligo
Abstract
Introduction: A 308-nm excimer lamp combined with topical medicines has been used to treat vitiligo. However, few studies have evaluated its efficacy and influencing factors in children.
Aim: We investigated the clinical effects and factors influencing the effectiveness of a 308-nm excimer lamp combined with 0.03% tacrolimus ointment in treating children with non-segmental vitiligo.
Material and methods: A retrospective interventional case-series study was performed on 73 patients with non-segmental vitiligo treated with combination therapy. The duration of treatment ranged from 1 to 24 months, and the total number of treatments ranged from 4 to 78 sessions. We evaluated different treatment factors, including the number of treatments with a 308-nm excimer lamp, location, dose, disease course, and adverse reactions.
Results: Overall, 105 leukodermas were treated: 36.2% had disappeared completely. The efficiency rate was 81.9% after a median treatment duration of 10.5 months. The treatment was most effective for the face and neck. Patients with a short disease duration showed a better response (disease duration shorter than 12 months). Reported adverse reactions were mild.
Conclusions: Treatment using a 308-nm excimer lamp and 0.03% tacrolimus ointment is a safe and valuable treatment for children with non-segmental vitiligo.
Keywords: drug reaction; phototherapy; tacrolimus; vitiligo.
Copyright: © 2022 Termedia Sp. z o. o.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial.J Dermatolog Treat. 2024 Dec;35(1):2296851. doi: 10.1080/09546634.2023.2296851. Epub 2023 Dec 21. J Dermatolog Treat. 2024. PMID: 38124534 Clinical Trial.
-
Comparison of the efficacy of 308-nm excimer lamp monotherapy with topical tacrolimus or clobetasol 17-propionate combination therapies in localized vitiligo.Photodermatol Photoimmunol Photomed. 2016 Sep;32(5-6):247-253. doi: 10.1111/phpp.12266. Epub 2016 Sep 27. Photodermatol Photoimmunol Photomed. 2016. PMID: 27552312 Clinical Trial.
-
Electrocautery Needling and the 308-nm Excimer Lamp: A Synergistic Combination for the Treatment of Stable Non-segmental Vitiligo.Dermatol Ther (Heidelb). 2020 Aug;10(4):695-705. doi: 10.1007/s13555-020-00395-7. Epub 2020 May 21. Dermatol Ther (Heidelb). 2020. PMID: 32441031 Free PMC article.
-
Effectiveness of a 308-nm excimer laser in treatment of vitiligo: a review.Lasers Med Sci. 2013 May;28(3):1035-41. doi: 10.1007/s10103-012-1185-1. Epub 2012 Aug 15. Lasers Med Sci. 2013. PMID: 22892613 Review.
-
Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review.An Bras Dermatol. 2016 Apr;91(2):187-95. doi: 10.1590/abd1806-4841.20164012. An Bras Dermatol. 2016. PMID: 27192518 Free PMC article. Review.
Cited by
-
ReCell Combined With NB-UVB for the Treatment of Extensive Stable Vitiligo: A Randomized Controlled Trial.J Cosmet Dermatol. 2025 Feb;24(2):e70032. doi: 10.1111/jocd.70032. J Cosmet Dermatol. 2025. PMID: 39936293 Free PMC article. No abstract available.
-
A randomized prospective study to compare the efficacy of 308-nm light-emitting diode and 308-nm excimer lamp in the treatment of facial vitiligo.Arch Dermatol Res. 2025 Jan 9;317(1):210. doi: 10.1007/s00403-024-03721-7. Arch Dermatol Res. 2025. PMID: 39786635 Clinical Trial.
References
-
- Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012; 51: 1206-12. - PubMed
-
- Frisoli ML, Harris JE. Vitiligo: mechanistic insights lead to novel treatments. J Allergy Clin Immunol 2017; 140: 654-62. - PubMed
-
- Wańkowicz-Kalińska A, van den Wijngaard RM, Tigges BJ, et al. . Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003; 83: 683-95. - PubMed
-
- van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. . Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129: 2220-32. - PubMed
-
- Novák Z, Bónis B, Baltás E, et al. . Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B 2002; 67: 32-8. - PubMed
LinkOut - more resources
Full Text Sources